Accurate Clinical Management, LLC

1. Organon LLC $504,899 109 payments
2. AstraZeneca UK Limited $259,761 9 payments
3. E.R. Squibb & Sons, L.L.C. $61,766 7 payments
4. AbbVie, Inc. $45,954 29 payments
5. Argenx US, Inc. $43,787 46 payments
6. Ucb SA $33,870 3 payments
7. Merck Sharp & Dohme Corporation $23,430 46 payments
8. Idorsia Pharmaceuticals US Inc $17,255 6 payments
9. Sekisui Diagnostics LLC $17,095 2 payments
10. Amgen Inc. $15,516 1 payment

1. Og-8175A-023 $278,507 99 payments
2. The purpose of this study is to characterise longterm safety and tolerability of intravenous anifrolumab A Multicentre Randomised Double blind Placebo Controlled Phase 3 Extension Study to Characterise the Long term Safety and Tolerability of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus $227,694 8 payments
3. Og-8175A-023 $226,392 10 payments
4. M15-572 $45,954 29 payments
5. Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patients with Primary Sjogrens Syndrome $43,787 46 payments
6. Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus $37,596 3 payments
7. A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. $33,870 3 payments
8. The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in adult subjects with moderately to severely active autoantibody positive systemic lupus erythematosus SLE $32,067 1 payment
9. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $22,291 20 payments
10. Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety and Efficacy of BMS-986165 in Participants with Systemic Lupus Erythematosus $18,643 1 payment

1. Patient care $504,899 109 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.